ScoreWhy is The Oncology Institute, Inc. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Low ability to service debt as the company has a high Debt to EBITDA ratio of -2.90 times
2
With a growth in Net Sales of 34.62%, the company declared Outstanding results in Jun 26
- The company has declared positive results for the last 4 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD 0.32 MM
- NET SALES(Q) Highest at USD 161.28 MM
- OPERATING PROFIT(Q) Highest at USD -2.78 MM
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 95.98%, its profits have risen by 32.9%
4
High Institutional Holdings at 56.56%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
- Their stake has increased by 3.68% over the previous quarter.
5
Market Beating performance in long term as well as near term
- Along with generating 95.98% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to The Oncology Institute, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is The Oncology Institute, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
The Oncology Institute, Inc.
80.83%
18.00
78.66%
S&P 500
16.06%
1.20
13.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
247.09%
EBIT Growth (5y)
-302.91%
EBIT to Interest (avg)
-18.48
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
8.08
Sales to Capital Employed (avg)
4.09
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
52.88%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-18.61
EV to EBIT
-9.52
EV to EBITDA
-11.79
EV to Capital Employed
9.73
EV to Sales
0.68
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-102.20%
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend24What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 0.32 MM
NET SALES(Q)
Highest at USD 161.28 MM
OPERATING PROFIT(Q)
Highest at USD -2.78 MM
OPERATING PROFIT MARGIN(Q)
Highest at -1.72 %
PRE-TAX PROFIT(Q)
Highest at USD -6.55 MM
NET PROFIT(Q)
Highest at USD -5 MM
RAW MATERIAL COST(Y)
Fallen by -21.49% (YoY
DEBTORS TURNOVER RATIO(HY)
Highest at 9.58 times
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for The Oncology Institute, Inc.
Operating Cash Flow
Highest at USD 0.32 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
Highest at USD 161.28 MM and Grown
In each period in the last five periodsMOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Operating Profit
Highest at USD -2.78 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Operating Profit trend is quite positive
Operating Profit (USD MM)
Operating Profit Margin
Highest at -1.72 % and Grown
In each period in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at USD -6.55 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD -5 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Net Sales
At USD 161.28 MM has Grown at 34.62%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Pre-Tax Profit
At USD -6.55 MM has Grown at 49.98%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Debtors Turnover Ratio
Highest at 9.58 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -21.49% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Depreciation
Highest at USD 1.84 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (USD MM)
Footer loading
